Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01660607 · ClinicalTrials.gov registry record · Phase 1
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT01660607: Completed Phase 1 study, sponsored by Stanford University.
NCT01660607 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 68 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01660607, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
This study looks at giving specific types of immune cells, called regulatory T cells and conventional T cells, to patients with blood cancers who are receiving a stem cell transplant. These cells are added back to help the immune system recover and reduce complications after the transplant.
Interventions
- BIOLOGICAL CD34+ Hematopoietic Progenitor Cells (HSPC)
- BIOLOGICAL Regulatory T-Cells (Treg)
- BIOLOGICAL Conventional T-Cells (Tcon)
- PROCEDURE Myeloablative Conditioning Regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2012-02-09 |
| Est. Completion | 2023-12-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01660607
The ClinicalTrials.gov registry entry for NCT01660607 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which CD34+ Hematopoietic Progenitor Cells (HSPC) is the first listed.
NCT01660607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01660607 about?
NCT01660607 is a clinical study titled "Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell". This study looks at giving specific types of immune cells, called regulatory T cells and conventional T cells, to patients with blood cancers who are receiving a stem cell transplant. These cells are added back to help the immune system recover and reduce complications after the transplant.
What is the current status of trial NCT01660607?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2012-02-09. Estimated completion is 2023-12-20.
What interventions are being tested in trial NCT01660607?
The interventions under investigation include: CD34+ Hematopoietic Progenitor Cells (HSPC) (BIOLOGICAL), Regulatory T-Cells (Treg) (BIOLOGICAL), Conventional T-Cells (Tcon) (BIOLOGICAL), Myeloablative Conditioning Regimen (PROCEDURE).
Who is sponsoring clinical trial NCT01660607?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.